Table 4 Distribution of piperaquine concentrations by month and day of measurement (median; IQR: Q1 to Q3)
Month | Day | Group 3 n = 20 (ng/mL) | Group 1 n = 50 (ng/mL) | P value (Wilcoxon rank sum test) |
|---|---|---|---|---|
0 | 0 | Below limit of quantification | Below limit of quantification | NA |
0 | 1 | 67.0 (43.9–89.1) | 64.9 (44.5–88.7) | 0.900 |
0 | 2 | 177.5 (125.0–213.5) | 139.0 (114.0–185.0) | 0.201 |
0 | 7 | 57.9 (40.8–86.5) | 68.2 (53.0–91.7) | 0.361 |
0 | AUC 0-7d ng*h/mL | 30,594.4 (21,015.2–36,429.7) | 23,151.6 (19,577.8–33,561.8) | 0.198 |
1 | 0 | 22.4 (15.0–29.9) | 19.8 (15.3–24.6) | 0.572 |
1 | 1 | 99.0 (59.0–162.5) | 104.0 (74.6–139.0) | 0.814 |
1 | 2 | 177.0 (134.5–246.0) | 153.5 (113.0–202.0) | 0.302 |
1 | 7 | 82.2 (66.8–5 128.5) | 82.1 (64.2–98.0) | 0.508 |
1 | AUC 0-7d ng*h/mL | 30,672.1 (20,366.4–38,646.6) | 24,221.4 (16,812.2–31,600.8) | 0.121 |
2 | 0 | 27.4 (21.8–46.8) | 33.8 (24.7–40.1) | 0.460 |
2 | 1 | 92.6 (66.6–131.5) | 111.5 (83.5–152.0) | 0.155 |
2 | 2 | 169.5 (116.0–257.0) | 179.0 (136.0–231.0) | 0.967 |
2 | 7 | 80.5 (56.7–134.5) | 86.5 (68.8–114.0) | 0.635 |
2 | AUC 0-7d ng*h/mL | 28,055.4 (19,286.0–42,462.6) | 27,652.0 (21,772.0 to 38,006.9) | 0.723 |
